Andrew Smith

Aaron Kowalski, PhD, the new CEO of the JDRF, says in a discussion about insulin pricing that action is needed not only by Congress, but also by insulin makers, health plans, and the executive branch. The most important goal: ending a crosspayment scheme that many blame for potentially deadly price increases.

Evidence-Based OncologyTM sat down with Andrew W. Lo, PhD, to discuss his proposals to increase investment in medical innovation and utilization by giving investors more ways to support both research organizations and individual patients.

Evidence is more robust on kidney function but not sufficient to make drug decisions, one expert said. A whole separate trial, called CREDENCE, is examining renal function in patients taking canagliflozin.

UnitedHealthcare has not released numbers on how many patients are affected by its exclusivity deal with Medtronic. While the initial press stories criticizing the transaction have died down, a JDRF initiative calls on insurers to preserve patient choice.

An experienced market watcher who has diabetes predicts the key to success will come down to one factor: ease of use.

An expert discusses her research on a critical period for patients with type 1 diabetes: moving from having parents make care decisions to taking control of disease management.

A leading diabetes educator discusses how the role of nutrition has evolved and how payers can do more to promote the role of education in helping patients improve their diets.

A recent report from the Government Accountability Office mostly concurs with CMS on a dispute over problems with the Medicare competitive bidding program, following an explosive study in Diabetes Care that found beneficiaries lost access to key supplies.

Second of 2 Parts: See Part 1, in Evidence-Based Diabetes Management, coverage of Patient-Centered Diabetes Care 2016.

For some patients newly diagnosed with type 2 diabetes, skipping metformin monotherapy and going straight to fixed-dose combinations with a DPP-4 inhibitor or an SGLT2 inhibitor makes sense, evidence shows.

Two competing insulin / GLP-1 combinations, one from Sanofi and the other from Novo Nordisk, are under review at FDA.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

The earliest studies involving diabetes therapy for Alzheimer’s are recruiting patients.

Did MannKind misjudge consumer demand, or are barriers from payers to blame for Afrezza's woes? A feature outlining the misfortunes and future plans for the only inhaled insulin on the market.

Choosing a therapy with fewer side effects can increase efficacy because patients stick with it, said Stacey McCullough, PharmD, of Tennessee Oncology.

Broad treatment guidelines may be based on relatively narrow trial data.

A thorough family history is the foundation of precision medicine, according to the 2015 president of the National Society of Genetic Counselors.

Disappointing sales were blamed on prior authorization, the FDA label restrictions, and the need for spirometry before doctors could write prescriptions.

An Interview with Joslin's George King, MD

Several clinical trials under way are examining whether a new class of therapy approved to treat type 2 diabetes can also treat type 1.

The decision by Cleveland Clinic's Steven Nissen, MD, to issue his own press release last spring after the cardiovascular outcomes trial was halted for Contrave turned plenty of heads in the pharmaceutical community. But Nissen and others involved in the saga see what happened with Orexigen as a one-time incident, not a flaw with the process for evaluating the safety of diabetes and obesity therapies.

A 5-year study reveals that the properly constructed diet, along with exercise aimed at muscle maintenance, can achieve long-term weight loss results.

On the eve of FDA's deadline for acting on the first of an expensive new class of cholesterol therapies, the chief medical officer of the nation's largest pharmacy benefit manager weighs on what steps it is taking on behalf of customers in this changing landscape.

Years of work has moved technology to the point of large-scale testing that is required before FDA approval and commercialization.

Trials that lead to FDA approval provide payers little information about the comparative differences between new therapies, and especially for their value for individual patients.

Two new insulins marketed by Sanofi offer improved options for patients: Toujeo is longer acting than its predecessor, Lantus. Afrezza, an inhaled insulin, is gaining praise from patients, if not from Wall Street.

Studies offer insights for patients with atrial fibrillation and type 2 diabetes mellitus, with more results to come.